CJC-1295 with DAC is a synthetic growth hormone releasing hormone analogue incorporating a Drug Affinity Complex modification, supplied as a lyophilised powder in a sealed single-use vial for laboratory and analytical research purposes only. Stock is held and dispatched from Australia with tracking, typically within 1-2 business days of order.
Specifications - Compound: CJC-1295 with DAC (also referenced as modified GRF 1-29 with Drug Affinity Complex). Format: lyophilised powder. Quantity: 5mg per vial. Purity: 98% minimum, analytically verified. Appearance: white lyophilised powder. Storage: 2-8 degrees C, sealed, protected from light. Intended use: laboratory research only.
Research context - CJC-1295 is a synthetic analogue of the first 29 amino acids of growth hormone releasing hormone, modified for improved stability. The DAC variant incorporates a Drug Affinity Complex intended to extend the compound's stable life in solution, and this distinguishes it from the non-DAC form. Laboratory research on this compound concentrates on comparative half-life studies between DAC and non-DAC variants, binding behaviour at the GHRH receptor in in-vitro models, and peptide stability under varying storage conditions. Genesis Peptides supplies CJC-1295 with DAC in lyophilised form to preserve compound integrity during transport and storage.
Handling and storage - Store the sealed vial refrigerated at 2-8 degrees C and protect it from heat and light. Reconstitute using bacteriostatic water and follow established laboratory handling protocols. Reconstituted material has a materially shorter stable life than lyophilised powder and should be kept refrigerated.
Compliance notice - This product is supplied strictly for laboratory research use only. Not for human consumption, veterinary use, or therapeutic application. Not listed with the TGA. Genesis Peptides does not provide medical, therapeutic, or clinical guidance.